KVISTGAARD, Denmark, May 27, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) announced today that a new planned trial of PROSTVAC® in combination with enzalutamide will be presented as "Trials in Progress" poster at the 2013 ASCO Annual Meeting in Chicago, IL from May 31 to June 4. Additionally, an abstract evaluating the safety profile of poxviral vaccines from 9 different clinical trials of PROSTVAC® and CV-301 has been published in connection with the conference.
- Abstract #TPS5104: "A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer" - General Poster Session, Genitourinary Prostate Cancer, Monday June 3, 2013 from 08:00 AM to 11:45 AM CT). http://abstracts2.asco.org/AbstView_132_116758.html
- Abstract #e16036: "Safety profile of recombinant poxviral TRICOM vaccines" http://abstracts2.asco.org/AbstView_132_115479.html
CONTACT: Anders Hedegaard, President & CEO Phone +45 23 20 30 64